zika
viru
zikv
infect
pregnanc
lead
sever
congenit
zika
syndrom
includ
microcephali
neurolog
malform
therapeut
agent
far
approv
treatment
zikv
infect
human
need
continu
effort
develop
effect
safe
antivir
drug
treat
zikvcaus
diseas
screen
natur
product
librari
herein
identifi
four
natur
product
antizikv
activ
vero
cell
includ
gossypol
curcumin
digitonin
conessin
except
curcumin
three
natur
product
report
antizikv
activ
among
gossypol
exhibit
strongest
inhibitori
activ
almost
zikv
strain
test
includ
six
recent
epidem
human
strain
mechanist
studi
indic
gossypol
could
neutral
zikv
infect
target
envelop
protein
domain
iii
ediii
zikv
contrast
natur
product
inhibit
zikv
infect
target
host
cell
cellassoci
entri
replic
stage
zikv
combin
gossypol
three
natur
product
identifi
studi
well
bortezomib
previous
report
antizikv
compound
exhibit
signific
combinatori
inhibitori
effect
three
zikv
human
strain
test
importantli
gossypol
also
demonstr
mark
potenc
four
serotyp
dengu
viru
denv
human
strain
vitro
taken
togeth
studi
indic
potenti
develop
natur
product
particularli
gossypol
lead
compound
broadspectrum
inhibitor
zikv
flavivirus
denv
fetal
death
approv
call
develop
safe
effect
therapeut
agent
zikv
infect
human
genom
zikv
encod
polyprotein
cleav
cellular
viral
proteas
form
three
structur
protein
includ
capsid
c
precursor
membranemembran
prmm
envelop
e
well
seven
nonstructur
protein
includ
life
cycl
zikv
involv
sever
crucial
step
includ
viral
attach
target
cell
receptor
cofactor
receptormedi
endocytosi
viral
entri
virusendosom
membran
fusion
postentri
posttransl
stage
life
cycl
e
protein
play
key
role
viral
entri
target
cell
subsequ
fusion
viru
cell
membran
thu
zikv
e
protein
serv
import
therapeut
target
zikv
infect
addit
zikv
flavivirus
denv
also
caus
signific
problem
human
four
antigen
serotyp
denv
lead
dengu
diseas
dengu
fever
dengu
hemorrhag
fever
dengu
shock
syndrom
case
increas
annual
therefor
develop
broadspectrum
antivir
inhibitor
use
treatment
infect
caus
zikv
flavivirus
includ
denv
studi
identifi
four
antizikv
inhibitor
screen
natur
product
librari
three
gossypol
digitonin
conessin
report
previous
zikv
infect
demonstr
broadspectrum
activ
natur
product
particularli
gossypol
multipl
zikv
strain
four
denv
serotyp
identifi
mechan
action
potenti
target
natur
product
reveal
enhanc
combinatori
effect
gossypol
natur
product
inhibit
zikv
infect
overal
studi
open
door
explor
develop
identifi
natur
product
lead
compound
broadspectrum
antizikv
antiflaviviru
inhibitor
materi
method
vero
cell
atcc
manassa
va
usa
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
penicillin
streptomycin
ps
cell
atcc
maintain
eagl
minim
essenti
medium
emem
supplement
fb
ps
zikv
strain
includ
human
strain
flr
rico
plcalzv
ibh
mosquito
strain
mex
rhesu
macaqu
strain
mr
figur
use
studi
zikv
strain
cultur
vero
cell
viral
titer
detect
standard
plaqueform
assay
denv
human
strain
includ
type
type
rico
type
rico
type
rico
figur
cultur
cell
viral
titer
determin
plaqueform
assay
zika
viru
zikv
mosquitoborn
flaviviru
genu
import
human
pathogen
includ
dengu
viru
denv
west
nile
viru
wnv
yellow
fever
viru
yfv
japanes
enceph
viru
jev
tickborn
enceph
viru
tbev
zikv
origin
isol
rhesu
macaqu
viru
recent
claim
worldwid
attent
owe
close
associ
congenit
zika
syndrom
cz
repres
microcephali
fetal
demis
central
nervou
system
abnorm
neurolog
complic
antivir
therapeut
treatment
zikvassoci
human
diseas
particularli
congenit
syndrom
plaqu
reduct
inhibit
assay
carri
measur
inhibitori
activ
natur
product
natur
product
collect
librari
microsourc
discoveri
system
gaylordsvil
ct
usa
infect
zikv
denv
previous
describ
briefli
zikv
strain
plaqueform
unit
pfu
multipl
infect
moi
incub
serial
dilut
natur
product
includ
curcumin
digitonin
conessin
well
antizikv
compound
control
bortezomib
dmso
volvol
control
h
compoundviru
mixtur
transfer
vero
cell
well
incub
h
gossypol
zikv
strain
pfu
moi
incub
serial
dilut
natur
product
h
unbound
gossypol
remov
centrifug
addit
gossypoltr
zikv
incub
vero
cell
h
cell
wash
thoroughli
pb
overlaid
dmem
contain
carboxymethyl
cellulos
fb
follow
vitro
cultur
day
stain
crystal
violet
inhibitori
activ
natur
product
test
describ
perform
follow
procedur
except
cell
use
infect
cell
cultur
day
stain
crystal
violet
inhibitori
concentr
natur
product
calcul
base
concentr
plaqu
reduct
respect
use
calcusyn
comput
program
describ
cytotox
natur
product
vero
zikv
cell
evalu
use
cell
count
sigma
st
loui
mo
usa
accord
manufactur
instruct
briefli
serial
dilut
natur
product
ad
equal
volum
cell
well
plate
cultur
day
cell
incub
solut
absorb
measur
nm
valu
use
micropl
reader
infinit
tecan
morrisvil
nc
usa
cytotox
concentr
natur
product
calcul
base
percent
cytotox
plaqu
reduct
inhibit
assay
carri
measur
inhibitori
activ
natur
product
natur
product
collect
librari
microsourc
discoveri
system
gaylordsvil
ct
usa
infect
zikv
denv
previous
describ
briefli
zikv
strain
plaqueform
unit
pfu
multipl
infect
moi
incub
serial
dilut
natur
product
includ
curcumin
digitonin
conessin
well
antizikv
compound
control
bortezomib
dmso
volvol
control
c
h
compoundviru
mixtur
transfer
vero
cell
well
incub
c
h
gossypol
zikv
strain
pfu
incub
serial
dilut
natur
product
c
h
unbound
gossypol
remov
centrifug
addit
gossypoltr
zikv
incub
vero
cell
c
h
cell
wash
thoroughli
pb
overlaid
dmem
contain
carboxymethyl
cellulos
fb
follow
vitro
cultur
c
day
stain
crystal
violet
inhibitori
activ
natur
product
test
describ
perform
follow
procedur
except
cell
use
infect
cell
cultur
c
day
stain
crystal
violet
inhibitori
concentr
ic
ic
natur
product
calcul
base
concentr
plaqu
reduct
respect
use
calcusyn
comput
program
describ
cytotox
natur
product
vero
zikv
cell
evalu
use
cell
count
sigma
st
loui
mo
usa
accord
manufactur
instruct
briefli
serial
dilut
natur
product
ad
equal
volum
cell
well
plate
cultur
c
day
cell
incub
solut
absorb
measur
nm
valu
use
micropl
reader
infinit
tecan
morrisvil
nc
usa
cytotox
concentr
cc
natur
product
calcul
base
percent
cytotox
use
calcusyn
comput
program
combinatori
cytotox
gossypol
natur
product
vero
cell
detect
use
similar
approach
describ
except
mix
gossypol
one
natur
product
curcumin
digitonin
conessin
bortezomib
throughli
ad
cell
experi
carri
previous
describ
modif
briefli
vero
cell
well
zikv
incub
differ
infect
step
describ
without
test
natur
product
specifi
concentr
gossypol
curcumin
digitonin
conessin
h
zikv
infect
h
infect
time
infect
antizikv
compound
temoporfin
bortezomib
includ
control
step
cultur
zikvor
compoundtr
cell
c
day
plaqu
visual
crystal
violet
stain
describ
percent
inhibit
natur
product
calcul
specif
follow
six
stage
zikv
infect
test
pretreat
zikv
pfu
natur
product
c
h
incub
cell
b
pretreat
cell
natur
product
c
h
incub
zikv
pfu
c
cotreat
cell
zikv
pfu
natur
product
c
h
cotreat
cell
zikv
pfu
natur
product
c
h
e
preincub
cell
zikv
pfu
c
h
incub
natur
product
c
h
f
preincub
zikv
pfu
cell
c
h
follow
incub
natur
product
c
h
bind
natur
product
zikv
fulllength
e
protein
aviva
system
biolog
san
diego
ca
usa
envelop
protein
domain
iii
ediii
protein
e
residu
fuse
ctermin
human
fc
carri
elisa
previous
describ
briefli
elisa
plate
precoat
protein
describ
c
overnight
block
fatfre
milk
c
h
serial
dilut
natur
product
dmso
neg
control
ad
plate
incub
c
h
plate
wash
pb
contain
pbst
incub
c
h
zikv
ediiispecif
human
monoclon
antibodi
mab
bind
zikv
fulllength
e
ediii
protein
plate
wash
pbst
incub
horseradish
peroxidas
hrp
conjug
antihuman
iggfab
abcam
cambridg
ms
usa
antibodi
c
h
tetramethylbenzidin
tmb
substrat
sigma
ad
plate
reaction
stop
n
h
absorb
nm
valu
measur
elisa
micropl
reader
tecan
ec
effect
concentr
calcul
base
calcusyn
comput
program
describ
determin
abil
gossypol
inhibit
bind
zikv
ediii
protein
ediiispecif
human
mab
ediiispecif
human
mab
control
elisa
carri
describ
except
serial
dilut
gossypol
dmso
neg
control
ad
presenc
mab
follow
sequenti
incub
hrpconjug
antihuman
iggfab
antibodi
tmb
substrat
detect
valu
percent
inhibit
natur
product
calcul
ic
concentr
caus
reduct
ediiimab
bind
obtain
use
calcusyn
comput
program
describ
interact
natur
product
zikv
fulllength
e
analyz
c
use
biacor
system
ge
healthcar
port
washington
ny
usa
previous
describ
briefli
zikv
e
immobil
sensor
chip
use
amin
coupl
kit
ge
healthcar
natur
product
variou
concentr
inject
analyt
pbsp
mm
phosphat
buffer
contain
mm
kcl
mm
nacl
surfact
ph
use
run
buffer
data
analyz
use
biacor
evalu
softwar
version
curv
fit
bind
model
potenti
combinatori
effect
gossypol
natur
product
carri
previous
describ
briefli
zikv
strain
flr
pfu
incub
serial
dilut
gossypol
c
h
unbound
gossypol
remov
centrifug
addit
gossypoltr
zikv
incub
vero
cell
c
h
presenc
dmem
contain
serial
dilut
three
natur
product
identifi
curcumin
digitonin
conessin
antizikv
compound
control
bortezomib
unbound
virus
natur
product
remov
cell
cultur
c
day
stain
crystal
violet
natur
product
without
combin
use
control
ic
valu
natur
product
calcul
use
calcusyn
comput
program
describ
natur
product
analyz
combinatori
effect
base
combin
index
ci
ic
valu
use
calcusyn
comput
program
previous
describ
specif
ci
valu
indic
synergi
antagon
respect
synergi
identifi
five
differ
categori
ci
valu
indic
strong
synerg
strong
synerg
synerg
moder
synerg
slight
synerg
respect
fold
enhanc
antizikv
potenc
express
ratio
molar
concentr
natur
product
test
alon
mixtur
use
formula
ic
alon
ic
mixtur
use
plaquebas
assay
initi
screen
natur
product
concentr
natur
product
librari
inhibitori
activ
infect
recent
zikv
human
strain
base
tabl
four
hit
natur
product
includ
gossypol
curcumin
digitonin
conessin
figur
select
sinc
demonstr
inhibitori
activ
zikv
infect
obviou
cytotox
vero
cell
observ
microscop
natur
product
subsequ
order
sigma
puriti
test
cytotox
use
cellbas
cytotox
assay
kit
cc
valu
rang
tabl
figur
among
natur
product
curcumin
previous
report
inhibit
zikv
infect
wherea
three
natur
product
previous
report
antizikv
activ
gossypol
curcumin
digitonin
conessin
retest
confirm
antizikv
strain
activ
ic
valu
respect
tabl
ic
valu
natur
product
zikv
strain
also
calcul
equal
respect
gossypol
curcumin
digitonin
conessin
figur
slightli
higher
respect
ic
valu
much
lower
correspond
cc
valu
tabl
initi
screen
natur
product
librari
identif
potenti
antizikv
inhibitor
natur
product
microsourc
discoveri
system
screen
primari
hit
inhibit
zikv
strain
primari
hit
high
cytotox
vero
cell
b
specif
hit
primari
hit
low
cytotox
specif
hit
avail
purchas
specif
hit
order
sigma
retest
confirm
antizikv
activ
specif
hit
display
ic
cc
total
primari
hit
inhibit
zikv
strain
infect
wherea
neg
control
dmso
inhibitori
activ
less
b
observ
cytotox
natur
product
microscop
cytotox
record
grade
natur
product
cytotox
greater
equal
grade
refer
high
cytotox
vero
cell
discard
test
virus
tabl
initi
screen
natur
product
librari
identif
potenti
antizikv
inhibitor
natur
product
microsourc
discoveri
system
screen
primari
hit
inhibit
zikv
strain
primari
hit
high
cytotox
vero
cell
b
specif
hit
primari
hit
low
cytotox
specif
hit
avail
purchas
specif
hit
order
sigma
retest
confirm
antizikv
activ
specif
hit
display
total
primari
hit
inhibit
zikv
strain
infect
wherea
neg
control
dmso
inhibitori
activ
less
b
observ
cytotox
natur
product
microscop
cytotox
record
grade
natur
product
cytotox
greater
equal
grade
refer
high
cytotox
vero
cell
discard
test
identifi
natur
product
studi
broadspectrum
activ
nine
addit
zikv
strain
includ
isol
differ
host
name
human
mosquito
rhesu
macaqu
differ
time
period
differ
countri
includ
mexico
panama
columbia
hondura
puerto
rico
thailand
nigeria
uganda
figur
result
show
natur
product
could
inhibit
infect
nine
zikv
strain
test
variou
valu
tabl
gossypol
exhibit
potent
inhibitori
activ
valu
rang
nine
zikv
strain
test
tabl
also
potent
bortezomib
antizikv
previous
report
compound
activ
compound
control
zikv
strain
test
tabl
valu
natur
product
select
zikv
strain
calcul
among
gossypol
lowest
valu
slightli
higher
valu
lower
valu
figur
confirm
strong
broadspectrum
antizikv
activ
identifi
natur
product
studi
broadspectrum
activ
nine
addit
zikv
strain
includ
isol
differ
host
name
human
mosquito
rhesu
macaqu
differ
time
period
differ
countri
includ
mexico
panama
columbia
hondura
puerto
rico
thailand
nigeria
uganda
figur
result
show
natur
product
could
inhibit
infect
nine
zikv
strain
test
variou
ic
valu
tabl
gossypol
exhibit
potent
inhibitori
activ
ic
valu
rang
nine
zikv
strain
test
tabl
also
potent
bortezomib
antizikv
previous
report
compound
activ
compound
control
zikv
strain
test
tabl
ic
valu
natur
product
select
zikv
strain
calcul
among
gossypol
lowest
ic
valu
slightli
higher
ic
valu
lower
cc
valu
figur
confirm
strong
broadspectrum
antizikv
activ
comparison
zikv
e
protein
sequenc
reveal
amino
acid
sequenc
highli
conserv
variat
occur
among
zikv
strain
use
evalu
inhibitori
activ
natur
product
includ
strain
test
earlier
figur
data
demonstr
identifi
natur
product
particularli
gossypol
abl
block
infect
diverg
human
mosquito
monkey
zikv
strain
isol
differ
time
period
countri
includ
six
recent
zikv
human
strain
confirm
broadspectrum
antizikv
activ
identifi
step
zikv
infect
life
cycl
block
natur
product
carri
timeofaddit
experi
incub
natur
product
zikv
cell
differ
time
point
zikv
cell
interact
calcul
percent
inhibit
base
number
plaqu
form
test
whether
natur
product
neutral
zikv
infect
inhibit
viral
entri
target
viral
protein
zikv
pretreat
natur
product
c
incub
host
cell
figur
evalu
whether
natur
product
bind
cellular
receptor
cofactor
block
virusreceptor
bind
cell
pretreat
natur
product
c
incub
zikv
figur
b
determin
whether
natur
product
inhibit
attach
zikv
target
cell
block
viruscel
membran
fusion
cell
cotreat
zikv
c
presenc
natur
product
figur
c
assess
whether
natur
product
inhibit
attach
zikv
target
cell
subsequ
viruscel
membran
fusion
cell
cotreat
zikv
natur
product
c
figur
investig
whether
natur
product
inhibit
zikv
fusion
cell
membran
entri
cell
cell
pretreat
zikv
c
first
incub
natur
product
c
figur
e
studi
whether
natur
product
inhibit
zikv
infect
postentri
stage
ie
viral
replic
virion
assembl
releas
cell
pretreat
zikv
incub
natur
product
c
figur
f
complet
approach
gain
insight
potenti
mechan
natur
product
respons
inhibit
zikv
infect
pretreat
zikv
gossypol
c
incub
target
cell
zikv
complet
lost
infect
wherea
maintain
infect
treatment
describ
figur
suggest
gossypol
effect
neutral
zikv
infect
target
viru
rather
cell
cellassoci
entri
replic
stage
result
curcumin
reveal
zikv
infect
block
curcumin
incub
zikv
c
coincub
zikv
cell
c
c
wherea
low
impact
zikv
infect
curcumin
pretreat
cell
postincub
zikvtreat
cell
c
c
respect
figur
result
suggest
curcumin
inhibit
zikv
infect
earli
stage
viral
entri
particularli
viral
attach
stage
pretreat
vero
cell
digitonin
zikv
cotreat
cell
zikv
digitonin
c
significantli
block
zikv
infect
wherea
preincub
cell
zikv
digitonin
c
pretreat
cell
zikv
c
digitonin
c
cotreat
cell
digitonin
zikv
c
inhibit
zikv
infect
figur
contrast
preincub
digitonin
zikv
effect
zikv
infect
figur
result
suggest
digitonin
could
directli
neutral
zikv
infect
inhibit
zikv
infect
bind
viral
receptor
inhibit
viral
entri
ie
attach
membran
fusion
postentri
step
data
conessin
indic
coincub
cell
conessin
zikv
c
postincub
conessin
zikvtreat
cell
c
c
result
inhibit
zikv
infect
wherea
pretreat
cell
conessin
zikv
incub
block
zikv
infect
nevertheless
preincub
conessin
zikv
c
cotreat
cell
conessin
zikv
c
low
effect
zikv
infect
figur
data
suggest
conessin
block
zikv
attach
host
cell
inhibit
zikv
infect
target
viruscel
fusion
postentri
step
step
inhibit
zikv
infect
proven
inhibit
zikv
infect
proven
respect
antizikv
compound
control
figur
therefor
data
confirm
potent
inhibitori
activ
identifi
natur
product
particularli
gossypol
block
zikv
infect
variou
stage
viral
life
cycl
antizikv
inhibitor
temoporfin
use
control
step
g
antizikv
entri
especi
inhibit
internalizationfus
step
inhibitor
use
control
step
b
e
antizikv
compound
bortezomib
use
control
step
h
replic
inhibitor
step
f
natur
product
curcumin
c
previous
report
inhibit
attach
zikv
host
cell
use
control
stage
c
percent
inhibit
calcul
presenc
absenc
serial
dilut
natur
product
data
express
mean
sem
n
experi
perform
vero
cell
repeat
three
time
similar
result
f
potent
antizikv
inhibitor
temoporfin
use
control
step
g
antizikv
entri
especi
inhibit
internalizationfus
step
inhibitor
use
control
step
b
e
antizikv
compound
bortezomib
use
control
step
h
replic
inhibitor
step
f
natur
product
curcumin
c
previous
report
inhibit
attach
zikv
host
cell
use
control
stage
c
percent
inhibit
calcul
presenc
absenc
serial
dilut
natur
product
data
express
mean
sem
n
experi
perform
vero
cell
repeat
three
time
similar
result
identifi
potenti
bind
region
natur
product
zikv
protein
first
carri
elisabas
approach
coat
plate
zikv
fulllength
e
ediii
protein
test
bind
affin
use
zikv
ediiispecif
mab
e
ediii
bind
result
reveal
gossypol
bound
potent
fulllength
e
ediii
protein
ec
valu
respect
wherea
curcumin
much
lower
bind
affin
zikv
fulllength
e
ediii
protein
figur
b
otherwis
digitonin
conessin
bortezomib
antizikv
compound
control
dmso
neg
control
bind
zikv
protein
test
figur
b
evalu
bind
gossypol
use
spr
assay
result
show
bind
affin
valu
zikv
e
protein
figur
zikv
fulllength
e
ediii
protein
figur
b
otherwis
digitonin
conessin
bortezomib
antizikv
compound
control
dmso
neg
control
bind
zikv
protein
test
figur
b
evalu
bind
gossypol
use
spr
assay
result
show
bind
affin
valu
zikv
e
protein
figur
sinc
gossypol
bound
zikv
e
protein
potenti
ediii
region
carri
elisa
complet
assay
identifi
possibl
bind
site
ediii
accordingli
zikv
ediii
protein
coat
plate
bind
zikv
ediii
ediiispecif
mab
zikv
edidiispecif
mab
control
evalu
presenc
serial
dilut
gossypol
result
show
gossypol
potent
block
bind
ediiispecif
mab
ediii
protein
dosedepend
manner
valu
respect
wherea
dmso
control
show
blockag
bind
figur
meantim
bind
control
mab
ediii
protein
obviou
inhibit
gossypol
detect
figur
zikv
ediiispecif
mab
previous
shown
potent
neutral
zikv
infect
recogn
epitop
includ
later
ridg
residu
zikv
ediii
protein
therefor
data
suggest
gossypol
like
bind
later
ridg
zikv
ediii
protein
block
ediiimab
bind
abil
gossypol
inhibit
bind
zikv
ediii
ediiispecif
neutral
mab
concentr
zikv
ediii
mab
respect
percent
inhibit
ediiimab
bind
measur
presenc
absenc
serial
dilut
gossypol
use
formula
ediiimabgossypol
ediiimab
turn
form
basi
calcul
inhibitori
concentr
ic
valu
zikv
edidiispecif
mab
dmso
use
control
data
express
mean
sem
n
experi
repeat
twice
similar
result
sinc
gossypol
bound
zikv
e
protein
potenti
ediii
region
carri
elisa
complet
assay
identifi
possibl
bind
site
ediii
accordingli
zikv
ediii
protein
coat
plate
bind
zikv
ediii
ediiispecif
mab
zikv
edidiispecif
mab
control
evalu
presenc
serial
dilut
gossypol
result
show
gossypol
potent
block
bind
ediiispecif
mab
ediii
protein
dosedepend
manner
ic
valu
respect
wherea
dmso
control
show
blockag
bind
figur
meantim
bind
control
mab
ediii
protein
obviou
inhibit
gossypol
detect
figur
zikv
ediiispecif
mab
previous
shown
potent
neutral
zikv
infect
recogn
epitop
includ
later
ridg
residu
zikv
ediii
protein
therefor
data
suggest
gossypol
like
bind
later
ridg
zikv
ediii
protein
block
ediiimab
bind
data
describ
demonstr
identifi
natur
product
gossypol
bound
strongli
zikv
e
protein
potenti
conserv
ediii
thu
block
ediiimab
bind
import
neutral
epitop
inhibit
viral
entri
target
cell
data
reason
explain
potent
broadspectrum
antivir
activ
gossypol
infect
multipl
zikv
strain
sinc
gossypol
demonstr
highest
antivir
activ
individu
zikv
strain
test
next
investig
potenti
combinatori
effect
combin
gossypol
three
natur
product
identifi
name
curcumin
digitonin
conessin
well
antizikv
compound
control
bortezomib
result
demonstr
signific
combinatori
inhibitori
effect
three
zikv
strain
flr
test
combin
gossypol
natur
product
ci
valu
rang
zikv
flr
strain
respect
tabl
combin
gossypol
natur
product
also
result
highest
enhanc
activ
among
three
zikv
strain
test
tabl
data
show
gossypol
combin
inhibitor
describ
increas
overal
inhibitori
activ
current
futur
emerg
zikv
strain
result
combinatori
effect
zikv
infect
could
exclud
possibl
observ
decreas
ic
presenc
anoth
natur
product
might
result
enhanc
cell
death
caus
natur
product
combin
therefor
also
assess
chang
cc
natur
product
alon
combin
compar
enhanc
cc
ic
zikv
strain
shown
tabl
cytotox
gossypol
combin
curcumin
digitonin
conessin
enhanc
cytotox
gossypol
combin
bortezomib
slightli
increas
much
lower
enhanc
activ
gossypol
combin
bortezomib
addit
cytotox
curcumin
bortezomib
respect
combin
gossypol
enhanc
cytotox
digitonin
conessin
combin
gossypol
slightli
increas
respect
still
lower
enhanc
activ
digitonin
conessin
combin
gossypol
moreov
ci
valu
gossypol
four
natur
product
test
greater
tabl
indic
combinatori
effect
cytotox
test
cell
result
suggest
observ
decreas
ic
valu
natur
product
combin
due
enhanc
cytotox
natur
product
note
gossypol
one
natur
product
includ
curcumin
digitonin
conessin
three
lead
natur
product
bortezomib
antizikv
compound
control
first
mix
accord
molar
ratio
identifi
combin
experi
zikv
strain
ad
vero
cell
determin
cytotox
combinatori
cytotox
natur
product
vero
cell
express
cc
identif
broadspectrum
antiflaviviru
inhibitor
crucial
treat
infect
caus
zikv
flavivirus
denv
henc
use
plaqu
assay
similar
zikv
evalu
antivir
activ
natur
product
infect
four
serotyp
denv
human
strain
cell
even
though
four
natur
product
could
inhibit
infect
result
show
gossypol
highest
potenc
infect
ic
valu
respect
tabl
also
activ
gossypol
ic
valu
slightli
higher
curcumin
ic
valu
tabl
cytotox
natur
product
cell
investig
cytotox
assay
cc
valu
rang
tabl
data
indic
potent
antidenv
activ
natur
product
particularli
gossypol
infect
four
denv
human
strain
low
cytotox
experi
perform
cell
cytotox
natur
product
cell
line
express
cc
inhibitori
activ
natur
product
infect
express
ic
data
express
mean
sem
n
experi
repeat
twice
similar
result
describ
earlier
gossypol
target
zikv
e
protein
potenti
ediii
although
number
variat
identifi
amino
acid
sequenc
e
protein
zikv
denv
strain
test
studi
figur
gossypol
could
still
inhibit
zikv
denv
strain
test
suggest
potenti
target
conserv
sequenc
zikv
denv
ediii
protein
data
explain
potent
broadspectrum
activ
gossypol
infect
least
two
flavivirus
includ
zikv
denv
develop
safe
effect
antivir
therapeut
urgent
need
treat
zikv
infect
zikvcaus
diseas
particularli
zikvassoci
microcephali
fetal
death
neurolog
diseas
identifi
four
smallmoleculebas
natur
product
name
gossypol
curcumin
digitonin
conessin
robust
antizikv
activ
vero
cell
among
gossypol
greatest
potenc
block
infect
zikv
almost
strain
isol
nine
countri
three
host
includ
six
recent
human
strain
associ
congenit
zika
syndrom
neurolog
malform
timeofadditionbas
mechanist
studi
indic
gossypol
could
neutral
zikv
infect
target
viru
rather
cell
cellassoci
zikv
entri
replic
step
inhibit
assay
reveal
gossypol
strongli
bound
zikv
e
protein
particularli
conserv
ediii
block
bind
zikv
ediii
ediiispecif
neutral
mab
ration
efficaci
broadspectrum
antizikv
activ
appear
bind
gossypol
zikv
eediii
protein
might
nonspecif
sinc
gossypol
also
activ
envelop
virus
includ
herp
simplex
viru
type
parainfluenza
viru
type
influenza
viru
potenti
toxic
side
effect
gossypol
human
might
good
idea
use
natur
product
drug
treat
human
diseas
includ
zikvassoci
microcephali
flaviviruscaus
diseas
nevertheless
goal
studi
identifi
best
activ
natur
product
modifi
improv
antivir
activ
druglik
properti
reduc
toxic
due
symmetr
natur
gossypol
molecul
better
opportun
defrag
structur
smaller
druglik
molecul
higher
activ
lower
toxic
therefor
suggest
use
gossypol
lead
molecul
rather
final
drug
unlik
gossypol
digitonin
conessin
neutral
zikv
directli
instead
inhibit
zikv
infect
variou
stage
life
cycl
includ
viral
attach
membran
fusion
postentri
step
notabl
digitonin
glycoalkaloid
saponin
deterg
wide
use
cell
membran
permeabil
agent
deterg
select
solubil
membran
protein
thu
antivir
activ
natur
product
like
nonspecif
comparison
conessin
appear
good
candid
decent
antizikv
activ
low
cytotox
higher
select
howev
steroid
alkaloid
might
ideal
optim
similar
gossypol
curcumin
may
directli
neutral
zikv
infect
seem
mainli
inhibit
earli
stage
attach
viru
infect
mechan
similar
seen
previou
report
use
differ
approach
data
also
demonstr
strong
vitro
abil
natur
productsgossypol
particularagainst
four
serotyp
denv
human
strain
low
cytotox
ic
valu
denv
similar
zikv
found
gossypol
bound
zikv
e
protein
potenti
ediii
suggest
may
recogn
highli
conserv
region
site
e
protein
zikv
denv
previous
curcumin
shown
potenti
inhibit
infect
direct
effect
viral
particl
product
variou
cellular
system
found
studi
literatur
report
antivir
activ
curcumin
serotyp
denv
inhibitori
effect
gossypol
digitonin
conessin
zikv
flavivirus
thu
present
studi
provid
rational
understand
antidenv
antizikv
mechan
natur
product
identifi
potenti
bind
site
viral
protein
except
demonstr
individu
vitro
antizikv
activ
natur
product
identifi
studi
particularli
gossypol
confirm
import
combinatori
antizikv
effect
gossypol
combin
natur
product
interest
note
combin
gossypol
curcumin
digitonin
conessin
result
increas
combinatori
effect
strain
compar
flr
strain
zikv
potenti
gossypol
potent
antiflr
activ
activ
test
individu
also
combin
enhanc
individu
antivir
activ
curcumin
digitonin
conessin
test
virus
shown
combin
gossypol
bortezomib
licens
proteasom
inhibitor
previous
report
inhibit
zikv
infect
led
signific
combinatori
activ
three
epidem
zikv
human
strain
test
therefor
studi
demonstr
possibl
combin
gossypol
natur
product
compound
enhanc
antivir
activ
overal
studi
evalu
antivir
activ
four
natur
product
vitro
among
three
newli
identifi
natur
product
strong
antizikv
abil
futur
observ
need
evalu
protect
efficaci
natur
product
individu
combin
use
defrag
small
druglik
molecul
case
gossypol
zikvcaus
congenit
infect
fetal
demis
avail
anim
model
modif
structur
gossypol
identif
deriv
better
antivir
activ
without
cytotox
would
essenti
develop
safe
effect
antizikv
agent
human
use
also
futur
studi
evalu
antivir
activ
modifi
gossypol
deriv
flavivirus
vitro
vivo
help
identif
effect
safe
panflaviviru
inhibitor
taken
togeth
broadspectrum
abil
identifi
natur
product
especi
gossypol
zikv
denv
infect
indic
potenti
develop
small
molecul
deriv
lead
compound
effect
antiflaviviru
inhibitor
supplementari
materi
follow
avail
onlin
http
figur
associ
inhibitori
activ
natur
product
zikv
strain
cytotox
figur
associ
inhibitori
activ
natur
product
zikv
strain
cytotox
figur
multipl
sequenc
align
amino
acid
aa
sequenc
e
protein
zikv
strain
human
strain
use
studi
author
contribut
sj
akd
ld
design
studi
yg
wt
nw
xl
perform
experi
analyz
data
yg
nw
carri
sequenc
align
analys
yg
sj
akd
ld
sc
wrote
revis
manuscript
